A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects inTP53
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects inTP53
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 167, Issue 2, Pages 149-161
Publisher
Wiley
Online
2014-07-21
DOI
10.1111/bjh.13042
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
- (2014) C. H. Geisler et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- The frequency ofTP53gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors
- (2014) Jitka Malcikova et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
- (2014) Patricia A.J. Muller et al. CANCER CELL
- The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
- (2014) J. C. Godbersen et al. CLINICAL CANCER RESEARCH
- Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center
- (2014) D M Stephens et al. LEUKEMIA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
- (2013) Michael Hallek AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
- (2013) P. Strati et al. BLOOD
- Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
- (2013) A. G. Ramsay et al. BLOOD
- Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia
- (2013) Leigh A. Humphries et al. BRITISH JOURNAL OF HAEMATOLOGY
- Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts
- (2013) Alexey V Danilov et al. Expert Review of Anticancer Therapy
- Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53 −/− mouse model and primary human leukemia cells
- (2013) J Liu et al. LEUKEMIA
- Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
- (2013) Jeffrey A. Jones et al. LEUKEMIA & LYMPHOMA
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
- (2013) Deborah M. Stephens et al. LEUKEMIA RESEARCH
- Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
- (2013) Francesca R. Mauro et al. LEUKEMIA RESEARCH
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
- (2012) G. Vasmatzis et al. BLOOD
- TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma
- (2012) D. W. Scott et al. BLOOD
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2012) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
- (2012) Andrew R. Pettitt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
- (2012) J A Woyach et al. LEUKEMIA
- Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
- (2011) W. G. Wierda et al. BLOOD
- Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
- (2011) X. C. Badoux et al. BLOOD
- The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia
- (2011) Ravin Garg et al. CANCER
- Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia
- (2011) Muller Fabbri JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia
- (2011) Martin Trbusek et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
- (2011) David Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia
- (2011) Regina Pileckyte et al. LEUKEMIA & LYMPHOMA
- DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance
- (2011) Alexey V. Danilov et al. PLoS One
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- ΔNp63 is an ectodermal gatekeeper of epidermal morphogenesis
- (2010) R Shalom-Feuerstein et al. CELL DEATH AND DIFFERENTIATION
- High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia
- (2010) Wei Xu et al. EUROPEAN JOURNAL OF CANCER
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
- (2010) T Zenz et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
- (2009) B. F. Eichhorst et al. BLOOD
- The microenvironment in mature B-cell malignancies: a target for new treatment strategies
- (2009) J. A. Burger et al. BLOOD
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
- (2009) T. Zenz et al. BLOOD
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
- (2009) C. S. Tam et al. BLOOD
- The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
- (2009) Francesc Bosch et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant p53 Gain-of-Function in Cancer
- (2009) M. Oren et al. Cold Spring Harbor Perspectives in Biology
- Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century
- (2008) H. Brenner et al. BLOOD
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- (2008) T. Zenz et al. BLOOD
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
- (2008) M. A. Phelps et al. BLOOD
- miR-34a as part of the resistance network in chronic lymphocytic leukemia
- (2008) T. Zenz et al. BLOOD
- Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
- (2008) G. Roue et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now